Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2015 Jul 9

PMID 26154294

Citations 7

Authors

Perwaiz M Meraj

Rajiv Jauhar

Avneet Singh

Affiliations

Soon will be listed here.

Abstract

The development of bare metal stent (BMS) was a major advancement over plain old balloon angioplasty (POBA) in the management of symptomatic coronary artery disease. BMS prevented restenosis by attenuating early arterial recoil and contraction; both seen commonly after POBA. However, the rate of clinically indicated target lesion repeat revascularization due to a process of in-stent restenosis (ISR) at 1 year remained relatively high (10 to 20 %), often due to excessive neointimal growth (Fischman et al. N Engl J Med. 331:496, 1994; Serruys et al. N Engl J Med. 331:489, 1994; Cutlip et al. J Am Coll Cardiol 40:2082, 2002). Stents with drug elution technology (DES) were developed to reduce the relatively high rate of ISR and subsequent repeat revascularization seen with BMS. Clinical trials have confirmed a reduction of as much as 50 to 70 % in target lesion revascularization by DES compared to BMS. These findings have led to the preferential use of DES in the majority of percutaneous coronary intervention (PCI). However, as DES require a longer period of dual antiplatelet therapy (DAPT) to prevent stent thrombosis, DES are not appropriate for all patients.

Citing Articles

Gao Z, Lei W, Gao E, Bhatia S Heliyon. 2024; 10(24):e40908.

PMID: 39720046 PMC: 11667596. DOI: 10.1016/j.heliyon.2024.e40908.

Individualizing Medicinal Therapy Post Heart Stent Implantation: Tailoring for Patient Factors.

Mohamad T, Jyotsna F, Farooq U, Fatima A, Kar I, Khuwaja S Cureus. 2023; 15(8):e43977.

PMID: 37746355 PMC: 10516147. DOI: 10.7759/cureus.43977.

Engineering biomaterials to prevent post-operative infection and fibrosis.

Josyula A, Parikh K, Pitha I, Ensign L Drug Deliv Transl Res. 2021; 11(4):1675-1688.

PMID: 33710589 PMC: 8238864. DOI: 10.1007/s13346-021-00955-0.

Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications.

Pacharra S, McMahon S, Duffy P, Basnett P, Yu W, Seisel S Front Bioeng Biotechnol. 2020; 8:991.

PMID: 32903548 PMC: 7438451. DOI: 10.3389/fbioe.2020.00991.

Biocompatible Polymer Materials with Antimicrobial Properties for Preparation of Stents.

Skrlova K, Malachova K, Munoz-Bonilla A, Merinska D, Rybkova Z, Fernandez-Garcia M Nanomaterials (Basel). 2019; 9(11).

PMID: 31683612 PMC: 6915381. DOI: 10.3390/nano9111548.

References

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato M, Feit F . Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012; 125(23):2873-91. DOI: 10.1161/CIRCULATIONAHA.112.097014. View

OGara P, Kushner F, Ascheim D, Casey Jr D, Chung M, de Lemos J . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration.... Catheter Cardiovasc Interv. 2013; 82(1):E1-27. DOI: 10.1002/ccd.24776. View

Parikh P, Jeremias A, Naidu S, Brener S, Shlofmitz R, Pappas T . Determinants of bare-metal stent use in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Invasive Cardiol. 2013; 25(3):114-7. View

Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K . Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation. 2012; 126(10):1225-36. DOI: 10.1161/CIRCULATIONAHA.112.104059. View

Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne R, Tiroch K . Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011; 378(9796):1071-8. DOI: 10.1016/S0140-6736(11)61255-5. View

Serruys P, Ong A, van Herwerden L, Sousa J, Jatene A, Bonnier J . Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005; 46(4):575-81. DOI: 10.1016/j.jacc.2004.12.082. View

Meredith I, Ormiston J, Whitbourn R, Kay I, Muller D, Bonan R . First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention. 2009; 1(2):157-64. View

Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G . Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. J Am Coll Cardiol. 2013; 61(5):545-50. DOI: 10.1016/j.jacc.2012.10.036. View

Sabate M, Raber L, Heg D, Brugaletta S, Kelbaek H, Cequier A . Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and.... JACC Cardiovasc Interv. 2013; 7(1):55-63. DOI: 10.1016/j.jcin.2013.07.012. View

10.

Park K, Lee J, Kang S, Ahn H, Yang H, Lee H . Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea.... J Am Coll Cardiol. 2013; 61(5):536-44. DOI: 10.1016/j.jacc.2012.11.015. View

11.

Serruys P, Silber S, Garg S, van Geuns R, Richardt G, Buszman P . Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010; 363(2):136-46. DOI: 10.1056/NEJMoa1004130. View

12.

Feres F, Costa R, Abizaid A, Leon M, Marin-Neto J, Botelho R . Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310(23):2510-22. DOI: 10.1001/jama.2013.282183. View

13.

Savage M, Douglas Jr J, Fischman D, Pepine C, King 3rd S, Werner J . Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997; 337(11):740-7. DOI: 10.1056/NEJM199709113371103. View

14.

Campeau L, Enjalbert M, LEsperance J, Bourassa M, Kwiterovich Jr P, Wacholder S . The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984; 311(21):1329-32. DOI: 10.1056/NEJM198411223112101. View

15.

Mehran R, Baber U, Steg P, Ariti C, Weisz G, Witzenbichler B . Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013; 382(9906):1714-22. DOI: 10.1016/S0140-6736(13)61720-1. View

16.

Lagerqvist B, James S, Stenestrand U, Lindback J, Nilsson T, Wallentin L . Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356(10):1009-19. DOI: 10.1056/NEJMoa067722. View

17.

Stone G, Ellis S, Cox D, Hermiller J, OShaughnessy C, Mann J . A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3):221-31. DOI: 10.1056/NEJMoa032441. View

18.

Fischman D, Leon M, Baim D, Schatz R, Savage M, Penn I . A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331(8):496-501. DOI: 10.1056/NEJM199408253310802. View

19.

Stone G, Ellis S, Cannon L, Mann J, Greenberg J, Spriggs D . Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005; 294(10):1215-23. DOI: 10.1001/jama.294.10.1215. View

20.

Wiisanen M, Abdel-Latif A, Mukherjee D, Ziada K . Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2011; 3(12):1262-73. DOI: 10.1016/j.jcin.2010.08.019. View